Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.68 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.60 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | CNR2 | P34972 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | CNR1 | P21554 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.60 |
| ▸ | PPARD | Q03181 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | TNKS | O95271 | 2/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxychavicol SCHEMBL43300 | 0.81 | XDH (1.00) | XDHGABRA1GABRB2ALDH1A1MAPT | |
| Hydroxychavicol SCHEMBL15676540 | 0.81 | XDH (1.00) | XDHGABRA1GABRB2ALDH1A1MAPT | |
| SCHEMBL25287635 | 0.81 | XDH (0.76) | XDHGABRA1GABRB2ALDH1A1MAPT | |
| SCHEMBL29414894 | 0.81 | XDH (0.76) | XDHGABRA1GABRB2ALDH1A1MAPT | |
| SCHEMBL4452326 | 0.78 | XDH (0.48) | XDHGABRA1GABRB2ALDH1A1MAPT | |
| SCHEMBL1006107 | 0.78 | XDH (0.70) | XDHGABRA1GABRB2ALDH1A1MAPT | |
| Hydroxychavicol SCHEMBL22717104 | 0.77 | XDH (0.81) | XDHGABRA1GABRB2ALDH1A1MAPT | |
| SCHEMBL680148 | 0.77 | XDH (0.63) | XDHGABRA1GABRB2ALDH1A1MAPT | |
| Hydroxychavicol SCHEMBL29440283 | 0.77 | XDH (0.81) | XDHGABRA1GABRB2ALDH1A1MAPT | |
| SCHEMBL5961687 | 0.76 | ALDH1A1 (0.47) | XDHGABRA1GABRB2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090214464-A1 | COMPOUNDS FOR FLAVIVIRIDAE TREATMENT | NOVARTIS AG (CH) | 2009-08-27 | — | — | US | claimed |
| US-20070275884-A1 | Use of modified cyclosporins for the treatment of hcv disorders | NOVARTIS AG (CH) | 2007-11-29 | — | — | US | claimed |
| EP-1797892-A1 | Use of modified cyclosporins for the treatment of HCV disorders | Novartis AG (CH) | 2007-06-20 | — | — | EP | claimed |
| EP-1663287-A1 | USE OF MODIFIED CYCLOSPORINS FOR THE TREATMENT OF HCV DISORDERS | Novartis AG (CH) | 2006-06-07 | — | — | EP | claimed |
| WO-2005021028-A1 | USE OF MODIFIED CYCLOSPORINS FOR THE TREATMENT OF HCV DISORDERS | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | claimed |
| EP-1797892-B1 | Use of modified cyclosporins for the treatment of HCV disorders | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-7968518-B2 | Use of modified cyclosporins for the treatment of HCV disorders | NOVARTIS AG (CH) | 2011-06-28 | — | — | US | disclosed |
| US-7897565-B2 | Compositions for HCV treatment | NOVARTIS AG (CH) | 2011-03-01 | — | — | US | disclosed |
| US-20100130408-A1 | USE OF MODIFIED CYCLOSPORINS | KOHJIMA MOTOYUKI | 2010-05-27 | — | — | US | disclosed |
| US-20090214464-A1 | COMPOUNDS FOR FLAVIVIRIDAE TREATMENT | NOVARTIS AG (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090104149-A1 | Compositions For HCV Treatment | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| US-20070275884-A1 | Use of modified cyclosporins for the treatment of hcv disorders | NOVARTIS AG (CH) | 2007-11-29 | — | — | US | disclosed |
| EP-1797892-A1 | Use of modified cyclosporins for the treatment of HCV disorders | Novartis AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| EP-1663287-A1 | USE OF MODIFIED CYCLOSPORINS FOR THE TREATMENT OF HCV DISORDERS | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005021028-A1 | USE OF MODIFIED CYCLOSPORINS FOR THE TREATMENT OF HCV DISORDERS | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130408-A1 | USE OF MODIFIED CYCLOSPORINS | CHP1, SERPINA6, FKBP2 | XDH 2109/4885GABRA1 1786/4885GABRB2 1217/4885 |
| US-20090104149-A1 | Compositions For HCV Treatment | HAVCR2, PPIB, FKBP1B | XDH 3558/4885GABRA1 1832/4885GABRB2 873/4885 |
| US-20070275884-A1 | Use of modified cyclosporins for the treatment of hcv disorders | HAVCR2, FKBP1A, FKBP2 | XDH 1942/4885GABRA1 1666/4885GABRB2 1477/4885 |
| US-20090214464-A1 | COMPOUNDS FOR FLAVIVIRIDAE TREATMENT | HAVCR2, PPIG, PPIH | XDH 912/4885GABRA1 1571/4885GABRB2 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.